No Data
No Data
Express News | Phio Pharmaceuticals Announces $1.15M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Express News | Phio Pharmaceuticals Corp: Intratumoral Injections Have Been Well Tolerated
Express News | Phio Pharmaceuticals: Positive Safety Monitoring Committee Recommendation to Continue to Third Dose Cohort in Its Clinical Study of Ph-762
Express News | Phio Pharmaceuticals Announced That The Safety Monitoring Committee Recommended Dose Escalation In Its Phase 1B Trial
Phio Pharmaceuticals Announces Publication In Frontiers In Immunology Announces Its Manuscript, Self-Delivering RNAi Immunotherapeutic PH-762 Silences PD-1 To Generate Local And Abscopal Anti-Tumor Efficacy, Has Been Published In The December, 2024...
Phio Pharmaceuticals Completes Enrollment In Second Cohort In Phase 1b Dose-Escalating Clinical Study
No Data
叮叮当 : Is it time to take off?